Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris

Acne Vulgaris Clinical Trial

Official title:

Clinical Evaluation of Venus Versa Diamonpolar Applicator Treatment Followed by AC Dual Applicator Treatment Using 2 Intense Pulsed Light Wavelength Bands for Facial Acne Vulgaris

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02924428
• Other study ID #: CS2715
• Status: Terminated
• Phase: N/A
• Start date: September 2016
• Est. completion date: October 2018

Study information

• Verified date: October 2020
• Source: Venus Concept
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy of facial acne vulgaris treatment using the Venus Versa Diamondpolar applicator in combination with the Venus Versa AC dual applicator using two intense pulsed light wavelength bands.

Description:

Multi-center, prospective, open-label study utilizing before-after study design. Up to 20 healthy subjects, age 18 - 55 years with acne vulgaris who wish to improve their skin appearance will be randomized to receive either Diamondpolar applicator (radio frequency and pulsed magnetic field) treatment followed by AC Dual applicator (intense pulsed light) treatment or AC Dual applicator (intense pulsed light) treatment alone using the Venus Versa system. Duration of subject participation will be approximately 10 weeks (4 weekly treatments with a follow-up visit scheduled 6 weeks after the last treatment).

The AC Dual applicator (IPL) is indicated for the treatment of acne vulgaris by using a blue light (415 nm) to target porphyrins produced by the P. acne bacteria, destroying the bacteria and uses the red light (630 nm) to help reduce inflammation, inhibit sebum production and improve healing.

The addition of the Diamondpolar applicator (RF and PEMF) treatment is thought to target the sebaceous gland, causing it to shrink and decrease sebum output

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 47
• Est. completion date: October 2018
• Est. primary completion date: June 5, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Fitzpatrick skin phototype I - VI

• Having mild to moderate acne vulgaris (as defined by the Acne Global Severity Scale) and have at least 10 inflammatory and 15 non-inflammatory lesions, but no nodulo-cystic lesions.

• Subject who can commit to all treatments and follow up.

Exclusion Criteria:

• Superficial metal or other implants in the treatment area.

• Current or history of cancer, or current condition of any type of cancer, or pre-malignant moles.

• Pregnancy and nursing.

• Patients with cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc)

• Diseases which may be stimulated by light at the wavelengths used, such as history of Systemic Lupus Erythematosus, Porphyria, and Epilepsy.

• Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.

• Poorly controlled endocrine disorders, such as Diabetes or Polycystic Ovary Syndrome.

• Any active condition in the treatment area, such as sores, Psoriasis, eczema, and rash.

• Tattoos, scars or piercings in the treated area.

• History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.

• Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelengths used, such as Isotretinoin (Accutane) within the last six months, tetracyclines, or St. John's Wort within the last two weeks.

• Any surgical procedure in the treatment area within the last three months or before complete healing.

• Treating over tattoo or permanent makeup.

• Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

• As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.

• Exposure to investigational product within 3 months (or designated half-life) prior to enrollment.

• Prior drugs, interventions, skin laser/light or another device for Acne treatment within 3 months of initial treatment or during the course of the study.

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Device:
• Venus Versa

Locations

Country	Name	City	State
United States	Sadick Research Group	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Venus Concept

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in Acne Vulgaris Appearance	Treatment will be considered successful if the appearance improves by at least 2 points on the 5-point Global Acne Assessment Score (GAAS) at 6 weeks post treatment as compared to baseline where 0 = No evidence of facial acne vulgaris, 1 (minimal) = Few non-inflammatory lesions (comedones) are present; a few inflammatory lesions (papules/pustules) may be present, 2 (mild) = Several to many non-inflammatory lesions (comedones) are present; a few inflammatory lesions (papules/pustules) are present, 3 (Moderate) = Many non-inflammatory (comedones) and inflammatory lesions (papules/pustules) are present; no nodulo-cystic lesions are allowed, 4 (Severe) = Significant degree of inflammatory disease; papules/pustules are a predominant feature; a few nodulo-cystic lesions may be present; comedones may be present. Lower number represents an improvement in acne vulgaris.	Week 10 (6 weeks after last treatment)
Secondary	Reduction of Inflammatory Lesions and Non-inflammatory Lesions	Reduction in the number of inflammatory lesions and non-inflammatory lesions counted on treatment area	Week 10 (6 weeks after last treatment)
Secondary	Subject Improvement Assessment in Treatment Area Appearance	Improvement as evaluated by subject using the Global Aesthetic Improvement Scale (GAIS) at 6 weeks after last treatment as compared to baseline where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.	Week 10 (6 weeks after last treatment)
Secondary	Subject Assessment of Pain and Discomfort Associated With Treatments	Pain and discomfort evaluated by subject using the 10 cm Visual Analog Scale where 0 cm is 'no pain' and 10 cm is 'intolerable pain'.	Immediately after each applicator treatment at Week 1
Secondary	Subject Satisfaction With Treatment Outcome	Satisfaction evaluated by subject using a 5-point Likert Scale where 4 = Very Satisfied, 3 = Satisfied, 2 Having No Opinion, 1 = Unsatisfied and 0 = Very Unsatisfied.	Week 10 (6 weeks after last treatment)
Secondary	Subject Assessment of Improvement in Acne Related 'Quality of Life'	Subject evaluated quality of life measured with the Acne Related Quality of Life Questionnaire at baseline where the total score varies from 0 to 114 with higher scores reflecting better quality of life.	Baseline
Secondary	Subject Assessment of Pain and Discomfort Associated With Treatments	Pain and discomfort evaluated by subject using the 10 cm Visual Analog Scale where 0 cm is 'no pain' and 10 cm is 'intolerable pain'.	Immediately after each applicator treatment at Week 6
Secondary	Subject Assessment of Improvement in 'Quality of Life'	Subject evaluated quality of life measured with the Acne Related Quality of Life Questionnaire at week 10 where the total score varies from 0 to 114 with higher scores reflecting better quality of life.	Week 10